Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL2934952 | 0.88 | PDPK1 (0.59) | PDPK1GDALMNAGMNNALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL10774603 | 0.88 | PDPK1 (0.59) | PDPK1GDALMNAGMNNALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL6241914 | 0.88 | PDPK1 (0.59) | PDPK1GDALMNAGMNNALDH1A1 | |
| Ribose (Furanose) SCHEMBL4284369 | 0.86 | HIF1A (0.46) | PDPK1GDALMNAGMNNALDH1A1 | |
| Ribose (Furanose) SCHEMBL17275115 | 0.81 | MGMT (0.38) | PDPK1GDALMNAHIF1ANT5E | |
| Adenine SCHEMBL580228 | 0.81 | PI4KA (0.58) | LMNAALDH1A1HTTRAB9AHIF1A | |
| Adenine SCHEMBL7746165 | 0.81 | PI4KA (0.58) | LMNAALDH1A1HTTRAB9AHIF1A | |
| Adenine SCHEMBL7624128 | 0.81 | PI4KA (0.58) | LMNAALDH1A1HTTRAB9AHIF1A | |
| Adenine SCHEMBL38386 | 0.81 | PI4KA (0.58) | LMNAALDH1A1HTTRAB9AHIF1A | |
| Dextrose SCHEMBL7886725 | 0.80 | PI4KA (0.56) | LMNAALDH1A1HTTRAB9AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-04 | — | — | US | claimed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | claimed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | claimed |
| JP-55045625-A | — | — | None | — | — | JP | disclosed |
| EP-1925675-B1 | Process for production of nucleoside compound | MITSUI CHEMICALS INC (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-1338654-B1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | MITSUI CHEMICALS INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1925675-A1 | Process for production of nucleoside compound | Mitsui Chemicals, Inc. (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-7038039-B2 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| EP-1179598-B1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | MITSUI CHEMICALS INC (JP) | 2005-08-10 | — | — | EP | disclosed |
| US-20040219646-A1 | Process for producing nucleoside compound | MITSUI CHEMICALS, INC. (JP) | 2004-11-04 | — | — | US | disclosed |
| CN-1476484-A | Process for producing nucleoside compound | 三井化学株式会社 | 2004-02-18 | — | — | CN | disclosed |
| EP-1338654-A1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1179598-A1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-02-13 | — | — | EP | disclosed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | disclosed |
| JP-S5545625-A | 2-METHYL-N6-SUBSTITUTED ADENINE-ARABINOSIDE AND ITS PREPARATION | AJINOMOTO CO INC | 1980-03-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | PNP, MTAP, GALE | PDPK1 253/4885GDA 248/4885LMNA 3037/4885 |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | PNP, GALE, MTAP | PDPK1 191/4885GDA 247/4885LMNA 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.